Is it okay to only take 50mg of dasatinib a day?

Dasatinib (Dasatinib) is a BCR::ABL1 tyrosine kinase inhibitor approved as a first-line treatment for chronic myeloid leukemia in chronic phase (CML-CP). The use of a lower dose of dasatinib (50 mg daily) showed better tolerability and improved outcomes compared with the standard dose. The study reports the latest results of a large cohort followed for 5 years.

In this study, patients with newly diagnosed chronic phase chronic myelogenous leukemia are eligible, and enrollment and response outcome criteria are standard, with 50 mg of dasatinib administered orally daily. Study results showed that at 3 months, 78 (96%) patients had BCR::ABL1 transcript (IS) ≤10%, and at 12 months, 65 (81%) patients had BCR::ABL1 transcript (IS) ≤0.1%. The cumulative incidence of complete cytogenetic, major molecular, and deep molecular responses over 5 years was 98%, 95%, and 82%, respectively. The failure rate (5%) and toxicity (5%) due to drag are low. The 5-year overall survival rate was 96% and the event-free survival rate was 90%. No transition to accelerated or embryonic stages was observed. Grade 3 to 4 pleural effusion occurs in 2% of patients.

Therefore, dasatinib 50mg daily is a safe and effective method to treat the chronic phase of newly diagnosed chronic myeloid leukemia. However, according to the latest clinical guidelines, for pediatric patients with CML-CP, the recommended starting dose is based on body weight, with the dose recalculated every 3 months, or more frequently if necessary. Therefore, the final dosage should be determined by the doctor based on the patient's specific situation, and the dosage should be adjusted based on the patient's condition and physical condition.